Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Molecular testing for the BCR-ABL1 fusion gene by real time quantitative polymerase chain reaction (RT-qPCR) is the most sensitive routine approach for monitoring the response to therapy of patients with chronic myeloid leukaemia. In the context of tyrosine kinase inhibitor (TKI) therapy, the technique is most appropriate for patients who have achieved complete cytogenetic remission and can be used to define specific therapeutic milestones. To achieve this effectively, standardization of the laboratory procedures and the interpretation of results are essential. We present here consensus best practice guidelines for RT-qPCR testing, data interpretation and reporting that have been drawn up and agreed by a consortium of 21 testing laboratories in the United Kingdom and Ireland in accordance with the procedures of the UK Clinical Molecular Genetics Society.

Original publication

DOI

10.1111/j.1365-2141.2011.08603.x

Type

Journal article

Journal

Br J Haematol

Publication Date

04/2011

Volume

153

Pages

179 - 190

Keywords

Fusion Proteins, bcr-abl, Humans, Ireland, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Molecular Biology, Monitoring, Physiologic, Practice Guidelines as Topic, Protein Kinase Inhibitors, RNA, Messenger, RNA, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Societies, Medical, United Kingdom